Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up – Here’s What Happened

Autolus Therapeutics plc (NASDAQ:AUTL)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $3.51, but opened at $3.72. Autolus Therapeutics shares last traded at $3.53, with a volume of 393,016 shares changing hands.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC restated a “buy” rating and set a $9.00 price target on shares of Autolus Therapeutics in a research report on Monday.

Autolus Therapeutics Trading Down 1.2 %

The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.09. The firm has a market cap of $875.44 million, a price-to-earnings ratio of -2.72 and a beta of 2.04. The company’s 50-day moving average price is $3.95 and its 200-day moving average price is $4.00.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.10). During the same period in the previous year, the business earned ($0.26) earnings per share. Equities analysts expect that Autolus Therapeutics plc will post -0.84 EPS for the current fiscal year.

Institutional Trading of Autolus Therapeutics

Hedge funds have recently bought and sold shares of the business. ProShare Advisors LLC purchased a new position in Autolus Therapeutics during the second quarter worth approximately $43,000. Daiwa Securities Group Inc. raised its holdings in shares of Autolus Therapeutics by 2,659.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after acquiring an additional 15,293 shares during the period. Herbst Group LLC acquired a new position in shares of Autolus Therapeutics during the 3rd quarter valued at about $91,000. Bayesian Capital Management LP purchased a new stake in shares of Autolus Therapeutics in the first quarter valued at about $100,000. Finally, B. Riley Wealth Advisors Inc. acquired a new stake in Autolus Therapeutics during the first quarter worth about $108,000. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.